Immunovant (IMVT) News Today $26.63 -1.42 (-5.06%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Immunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Principal Financial Group Inc.Principal Financial Group Inc. increased its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 69.9% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 951,124 shares of the company's stock after purchNovember 13, 2024 | marketbeat.comImmunovant’s Strategic Advancements and Promising Clinical Developments Boost Buy RatingNovember 11, 2024 | markets.businessinsider.comStrategic Advancement in RA and Robust Pipeline Bolster Immunovant’s Buy RatingNovember 9, 2024 | markets.businessinsider.comImmunovant’s Strategic Advances in Autoimmune TherapiesNovember 9, 2024 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Misses Estimates By $0.15 EPSImmunovant (NASDAQ:IMVT - Get Free Report) posted its quarterly earnings data on Thursday. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.15). During the same quarter last year, the business earned ($0.45) EPS.November 8, 2024 | marketbeat.comPromising Potential in Immunovant’s FcRn Program: Buy Rating on Advancements in Rheumatoid Arthritis and Strategic Trial DesignNovember 8, 2024 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $51.00 price objective on shares of Immunovant in a report on Friday.November 8, 2024 | marketbeat.comImmunovant’s Promising Pipeline and Strategic Advancements Justify Buy RatingNovember 8, 2024 | markets.businessinsider.comImmunovant price target raised to $58 from $52 at StifelNovember 7, 2024 | markets.businessinsider.comImmunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024November 7, 2024 | globenewswire.comPromising Phase 2a Results for Immunovant’s Batoclimab Support Buy RatingNovember 4, 2024 | markets.businessinsider.comEmerald Advisers LLC Has $7.13 Million Holdings in Immunovant, Inc. (NASDAQ:IMVT)Emerald Advisers LLC decreased its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 13.4% in the third quarter, according to its most recent 13F filing with the SEC. The firm owned 250,039 shares of the company's stock after selling 38,525 shares during the period. Emerald Advisers LLC oNovember 4, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Bought by abrdn plcabrdn plc grew its holdings in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 19.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 478,757 shares of the company's stock after acquiring an additional 78,035 shares duriNovember 2, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Given Consensus Rating of "Buy" by AnalystsImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) has been given an average recommendation of "Buy" by the eleven research firms that are currently covering the company, Marketbeat.com reports. Eleven equities research analysts have rated the stock with a buy recommendation. The average twelve-montOctober 30, 2024 | marketbeat.comImmunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual MeetingOctober 29, 2024 | globenewswire.comJay S. Stout Sells 2,740 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockOctober 27, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) CTO Sells $80,912.20 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CTO Jay S. Stout sold 2,740 shares of the stock in a transaction on Wednesday, October 23rd. The shares were sold at an average price of $29.53, for a total value of $80,912.20. Following the completion of the transaction, the chief technology officer now directly owns 142,186 shares in the company, valued at approximately $4,198,752.58. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.October 25, 2024 | marketbeat.comRoivant Sciences: Good Value, But Near-Term Catalysts Could Bring VolatilityOctober 22, 2024 | seekingalpha.comImmunovant’s Promising Advances in GD Treatment and Strong Financial Position Bolster Positive OutlookOctober 19, 2024 | markets.businessinsider.comImmunovant, Inc. (NASDAQ:IMVT) Insider Sells $91,782.52 in StockOctober 19, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) CFO Eva Renee Barnett Sells 3,271 SharesOctober 19, 2024 | insidertrades.comImmunovant: Switching Lead Candidates Increases RiskOctober 14, 2024 | seekingalpha.comThe Manufacturers Life Insurance Company Decreases Stake in Immunovant, Inc. (NASDAQ:IMVT)The Manufacturers Life Insurance Company decreased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 51.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 37,626 shares of thOctober 14, 2024 | marketbeat.comPeter Salzmann Sells 4,460 Shares of Immunovant, Inc. (NASDAQ:IMVT) StockOctober 12, 2024 | insidertrades.comImmunovant, Inc. (NASDAQ:IMVT) CEO Sells $131,837.60 in StockImmunovant, Inc. (NASDAQ:IMVT - Get Free Report) CEO Peter Salzmann sold 4,460 shares of Immunovant stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $29.56, for a total value of $131,837.60. Following the completion of the transaction, the chief executive officer now owns 1,003,884 shares in the company, valued at $29,674,811.04. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.October 11, 2024 | marketbeat.comImmunovant (NASDAQ:IMVT) Receives "Outperform" Rating from Raymond JamesRaymond James reaffirmed an "outperform" rating and issued a $36.00 price target on shares of Immunovant in a report on Thursday.October 10, 2024 | marketbeat.comMillennium Management LLC Sells 277,575 Shares of Immunovant, Inc. (NASDAQ:IMVT)Millennium Management LLC lessened its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 50.2% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 275,352 shares of the company's stock afterOctober 10, 2024 | marketbeat.comOppenheimer Increases Immunovant (NASDAQ:IMVT) Price Target to $53.00Oppenheimer upped their price objective on Immunovant from $47.00 to $53.00 and gave the company an "outperform" rating in a research report on Wednesday.October 9, 2024 | marketbeat.comDimensional Fund Advisors LP Reduces Stake in Immunovant, Inc. (NASDAQ:IMVT)Dimensional Fund Advisors LP cut its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 13.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 494,689 shares of the company's stock after selling 78,758 shares during the period. DimOctober 6, 2024 | marketbeat.comAlgert Global LLC Grows Stock Position in Immunovant, Inc. (NASDAQ:IMVT)Algert Global LLC raised its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 134.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 120,938 shares of the company's stock after buying anOctober 2, 2024 | marketbeat.comBuy Rating for Immunovant: A New Hope in Graves’ Disease TreatmentOctober 1, 2024 | markets.businessinsider.comIs Immunovant, Inc. (IMVT) the Worst Performing Stock to Buy on the Dip?October 1, 2024 | finance.yahoo.comImmunovant (NASDAQ:IMVT) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reissued a "buy" rating and set a $51.00 price target on shares of Immunovant in a research report on Monday.September 30, 2024 | marketbeat.comBlue Owl Capital Holdings LP Decreases Stock Holdings in Immunovant, Inc. (NASDAQ:IMVT)Blue Owl Capital Holdings LP cut its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 20.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 80,000 shares of the company's stock after sellingSeptember 28, 2024 | marketbeat.comArmistice Capital LLC Has $89.68 Million Position in Immunovant, Inc. (NASDAQ:IMVT)Armistice Capital LLC raised its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 57.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,396,909 shares of the company's stock after buying an additional 1,232,909 shares duSeptember 26, 2024 | marketbeat.comBuy Rating Backed by Promising Batoclimab Results for Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comImmunovant (NASDAQ:IMVT) Trading Up 2.7%Immunovant (NASDAQ:IMVT) Stock Price Up 2.7%September 25, 2024 | marketbeat.comProfund Advisors LLC Sells 18,864 Shares of Immunovant, Inc. (NASDAQ:IMVT)Profund Advisors LLC lowered its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 41.9% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 26,140 shares of the company's stock after sellingSeptember 25, 2024 | marketbeat.comBuy Recommendation: Immunovant’s Novel Therapy Addresses Unmet Needs in Graves’ Disease TreatmentSeptember 25, 2024 | markets.businessinsider.comLogos Global Management LP Sells 1,200,000 Shares of Immunovant, Inc. (NASDAQ:IMVT)Logos Global Management LP cut its position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 67.6% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 575,000 shares of the company's stock after selling 1,200,000September 24, 2024 | marketbeat.comRubric Capital Management LP Invests $1.55 Million in Immunovant, Inc. (NASDAQ:IMVT)Rubric Capital Management LP acquired a new position in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 58,624 shares of the company's stock, valuedSeptember 21, 2024 | marketbeat.comAcelyrin: Straight Move To Phase 3 TED Studies Makes It Must WatchSeptember 20, 2024 | seekingalpha.comWINTON GROUP Ltd Takes Position in Immunovant, Inc. (NASDAQ:IMVT)WINTON GROUP Ltd acquired a new stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,675 shares of the company's stock, valued at approximately $5September 18, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Sold by TD Asset Management IncTD Asset Management Inc reduced its position in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 46.7% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 36,800 shares of the company's stock after selling 32,242 shares during the qSeptember 15, 2024 | marketbeat.comFirst Turn Management LLC Buys 182,535 Shares of Immunovant, Inc. (NASDAQ:IMVT)First Turn Management LLC raised its stake in Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 35.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 695,428 shares of the company's stock afSeptember 13, 2024 | marketbeat.comAnalysts Offer Predictions for Immunovant, Inc.'s FY2026 Earnings (NASDAQ:IMVT)Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities researchers at Leerink Partnrs dropped their FY2026 EPS estimates for shares of Immunovant in a note issued to investors on Monday, September 9th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($2.82) per share foSeptember 12, 2024 | marketbeat.comImmunovant, Inc. (NASDAQ:IMVT) Shares Acquired by Bank of New York Mellon CorpBank of New York Mellon Corp raised its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT - Free Report) by 12.6% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 250,339 shares of the company's stock after acquiring an addSeptember 12, 2024 | marketbeat.comBuy Rating Affirmed for Immunovant on Strong Batoclimab Trial Results and Promising Commercial ProspectsSeptember 11, 2024 | markets.businessinsider.comWhat the Options Market Tells Us About ImmunovantSeptember 11, 2024 | benzinga.comImmunovant’s Promising Clinical Data and Market Potential Justify a Buy RatingSeptember 10, 2024 | markets.businessinsider.com Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address The centerpiece of Trump’s crypto’s masterplan … (Ad)Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin conference in Nashville … Where he told an adoring crowd that the U.S. would become … “The crypto capital of the planet and the Bitcoin superpower of the world.” Click here to find out more about what could be Trump and JD Vance’s favorite coin. IMVT Media Mentions By Week IMVT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMVT News Sentiment▼1.140.55▲Average Medical News Sentiment IMVT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMVT Articles This Week▼35▲IMVT Articles Average Week Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies UTZ News Today ADV News Today HYLN News Today MPLN News Today GMAB News Today SMMT News Today VTRS News Today PCVX News Today SRPT News Today CTLT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMVT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts